QRG Capital Management Inc. Purchases 3,229 Shares of DexCom, Inc. $DXCM

QRG Capital Management Inc. lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 14.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,978 shares of the medical device company’s stock after buying an additional 3,229 shares during the quarter. QRG Capital Management Inc.’s holdings in DexCom were worth $2,268,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Brighton Jones LLC boosted its stake in DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after acquiring an additional 11,946 shares in the last quarter. Merit Financial Group LLC increased its position in DexCom by 102.3% during the 1st quarter. Merit Financial Group LLC now owns 5,933 shares of the medical device company’s stock valued at $405,000 after buying an additional 3,000 shares in the last quarter. Gateway Investment Advisers LLC increased its position in DexCom by 13.9% during the 1st quarter. Gateway Investment Advisers LLC now owns 3,108 shares of the medical device company’s stock valued at $212,000 after buying an additional 380 shares in the last quarter. Wedmont Private Capital bought a new position in DexCom during the 1st quarter valued at approximately $214,000. Finally, Park Avenue Securities LLC grew its stake in shares of DexCom by 35.5% in the first quarter. Park Avenue Securities LLC now owns 18,086 shares of the medical device company’s stock worth $1,235,000 after acquiring an additional 4,739 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on DXCM. Oppenheimer cut DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 10th. Morgan Stanley increased their price target on shares of DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Robert W. Baird decreased their price objective on shares of DexCom from $112.00 to $90.00 and set an “outperform” rating for the company in a report on Friday, September 26th. Finally, Truist Financial started coverage on DexCom in a research note on Monday, June 16th. They set a “buy” rating and a $102.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $97.42.

Insider Transactions at DexCom

In related news, Director Mark G. Foletta sold 2,750 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the sale, the director directly owned 51,121 shares in the company, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the sale, the executive vice president owned 94,102 shares of the company’s stock, valued at $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,849 shares of company stock worth $564,733 in the last ninety days. Insiders own 0.32% of the company’s stock.

DexCom Stock Down 0.5%

Shares of DexCom stock opened at $66.03 on Wednesday. The company has a market cap of $25.89 billion, a price-to-earnings ratio of 45.85, a price-to-earnings-growth ratio of 1.39 and a beta of 1.47. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The company’s 50 day moving average is $75.38 and its 200 day moving average is $77.80. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the previous year, the business earned $0.43 EPS. The company’s quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.